Abstract
This paper summarises the design, analysis and results of an international study to improve knowledge of the reasons for non-compliance with drug therapy for a largely asymptomatic chronic disease. Market research methods were chosen in order to assess the viability and value of investing in a more expensive and time-consuming definitive longitudinal clinical study. It also leads to important conclusions in its own right. After a programme of qualitative research (focus groups and individual depth interviews) followed by quantitative research we show results that could, in themselves, lead to action and demonstrate that investment in a longitudinal clinical investigation could lead to action with benefits for public health as well as the pharmaceutical industry.
Get full access to this article
View all access options for this article.
